World Wide Trends - Pagina 11 di 17

11 agosto 2023

Asia-Pacific Grew the Fastest in Sleep Apnea Devices Industry

As per a report published by a market research institution, P&S Intelligence, the sleep apnea devices industry will grow at a compound annual growth rate of 7.2%, to touch USD 13,386.5 million by 2030.

This growth of the industry is because of the increasing incidence of OSA, unhealthy routines of individuals, changes in diet and sleep patterns, and enormous work pressure.

With the development of cutting-edge products, there is an increase in the acceptance of portable devices. For example, products equipped with additional features, for example the usage of an algorithm and pressure sensor for determination of the best pressure, are there in the market.

Therapeutic devices had the larger share. The industry has availability of numerous therapeutic devices for treating sleep apnea in which sleeping aids support the treatment. It will also be faster growing category, advancing at a rate of about 9% by the end of this decade. This growth will mainly be led by the growing OSA cases globally.

North America led the sleep apnea devices market, with about 45% share in 2022. This is because of the increasing incidence of sleeping ailments. Also, the rise in the incidence of a number of health conditions, for example obesity and heart diseases, which are risky factors for sleep apnea will also play a part in the growth of the industry in the region.

The growing elderly population also plays a key role in powering the market growth. With elderly, people suffer from health issues, as a result of psychological features and changes in cardiac rhythm, therefore making them more vulnerable to sleep ailments.

Furthermore, OSA and insomnia are the most common sleeping conditions in aged people. For improving the quality of life and ensuring a healthy lifestyle amongst the elderly population, the requirement for such devices is rapidly on the rise.

The increasing incidence of OSA, and the changing lifestyle of the people has a lot to do with the increasing demand for sleep apnea devices all over the world.

10 agosto 2023

United States Medical Equipment Maintenance Industry was Dominated by Texas

U.S. Medical Equipment Maintenance Industry

The United States medical equipment maintenance market will power at a rate of 9.2% in the years to come, to reach USD 21,358.3 million by 2030, as stated by a market research institution, P&S Intelligence.

This growth will be driven by the progressions in the medical device industry, increasing consciousness on preventive medical equipment upkeep, and a strict regulatory environment.

Preventive maintenance dominated the industry. This will also have the highest growth rate in the years to come. This can be credited to the growing acceptance of AMC policies by hospitals and other users in the nation, because of the numerous reimbursements related to them.

Private-sector organizations will have the larger share in 2030. This has a lot to do with the budding private-sector healthcare sector and increasing healthcare spending.

Among all the states, Texas dominated the industry in the past, and it is expected to grow the fastest in the years to come.

This is mainly due to the presence of a high number of hospitals in the state, coupled with the growing healthcare expenditure. State agencies, such as the HHSC, DADS, and Texas DSHS, had ~83% of all healthcare expenditure in the state on an annual basis.

The users in the medical equipment maintenance market of the nation are becoming more persuaded toward entering into multi-vendor contracts, for reducing the intricacies and further expenses related to separate services delivered under agreements with the builders of medical equipment.

In the country, numerous tech advanced medical devices and associated products are put to use by healthcare specialists and governments to offer best in-class amenities to patients.

As these high-tech medical devices necessitate steady maintenance, software updates, and other kinds of services, their snowballing acceptance will drive the market in the years to come.

The U.S. has a strict regulatory framework, which makes the maintenance of medical equipment a compulsory requirement for users.

According to the regulations, hospitals must follow OEMs suggest preventive maintenance procedures and programs, unless a waiver was executed and accepted by the health department.

With these kinds of regulations in place, the acceptance of medical equipment upkeep services by hospitals and other healthcare facilities will increase, powering the market in the near future.

This market is highly diversified, because of the occurrence of more than a few key players. Recently, major players have taken a number of strategic measures, for example partnerships, mergers and accusations , and facility developments, to gain a competitive edge in the market.

It is because of the growing consciousness on preventive medical equipment upkeep, the demand for medical equipment maintenance, will increase in the years to come in the U.S.

7 agosto 2023

North America Is Dominating Embolotherapy Industry

The global embolotherapy market is experiencing growth and is projected to reach 6,447.1 million by 2030, according to P&S Intelligence. This growth can be ascribed to the rising patient pool, mounting occurrence of chronic and lifestyle-related illnesses, growing healthcare investments, and advancing healthcare infrastructure.

In recent years, embolic agents led the industry, on the basis of product. The growing utilization of embolic agents in numerous interventional radiology procedures is the major factor for this product category’s supremacy in the industry.

Moreover, because of the improvements in such agents, including drug-eluting microspheres, standardized microspheres for bland embolization, and radioactive yttrium-90 (Y-90) microspheres, for curing primary or secondary liver illness, the category is projected to advance at a higher rate in the coming few years.

In the coming few years, the transcatheter arterial embolization category is projected to be the fastest-rising category, on the basis of procedure. This can be credited to the thriving requirement for minimally invasive procedures and the quickly rising elderly populace.

Furthermore, TAE is effective and well-tolerated in patients with ruptured hepatocellular carcinoma (HCC), and it is favored over transarterial radioembolization (TARE) and transarterial chemoembolization (TACE).

In recent years, North America led the embolotherapy market, and it is projected to grip the largest industry share in the future as well. The growing occurrence of signs that need embolization procedures, well-known healthcare infrastructure, and the growth of progressive embolic agents by the players functioning in the continent are some of the key factors for the development of the North American industry.

The embolotherapy industry is experiencing development mainly because of the surge in the count of patients looking for embolization for the treatment of HCC, aneurysms, renal cell carcinoma (RCC), and varicose veins.

As per the Centers for Disease Control and Prevention (CDC), in 2018, aortic aneurysms were accountable for 9,923 demises in the U.S., which displays the unmet medicinal requirement for these procedures. Thus, the growing patient pool fortifies the requirement for embolization procedures.

The extended exposure to four modifiable lifestyle behaviors, mainly physical inactivity, smoking, alcohol consumption, and unhealthy diet, commonly results in chronic illnesses, such as diabetes, stroke, metabolic syndrome, obesity, chronic obstructive pulmonary illness, and numerous kinds of cancer.

Chronic illnesses are a key healthcare load impacting high-income as well as low- and middle-income nations (LMICs). Hepatitis, cancer, and central nervous system syndromes are some of the chronic illnesses that need progressive treatment. Therefore, the surge in the occurrence of chronic and lifestyle-related illnesses is boosting the embolotherapy industry worldwide.

Hence, the growing patient pool, mounting occurrence of chronic and lifestyle-related illnesses, growing healthcare investments, and advancing healthcare infrastructure, such factors are propelling embolotherapy market.

4 agosto 20234 agosto 2023

APAC To Observe Fastest Growth In the Private Healthcare Insurance Industry

As per a report by P&S Intelligence the healthcare insurance market is growing rapidly, and it will continue like this in the years to come. This is mainly attributed to the increasing elderly population, rising gross domestic product and healthcare expenses, and growing prevalence of chronic illnesses across the world.

Private healthcare insurance companies provide a variety of plans for disease, income protection, and medical. Medical insurance denotes the policy of health insurance that covers high deductible medical expenses. This policy covers specific expenses on a limited amount, for instance, emergency services, ambulatory patient services, and hospital bed expenditures.

Some prominent international players in the private healthcare insurance industry include AXA Group, Allianz SE, Aetna Inc., Aviva plc, Cigna Corporation, Zurich Insurance Group, GIE BNP Paribas Cardif, Continentale Krankenversicherung a.G, Assicurazioni Generali S.p.A., and British United Provident Association Limited. These companies are present in Germany, the U.S., France, Spain, Italy, the United Kingdom, China, Switzerland, Japan, Australia, India, Mexico, and Brazil.

Established in 1890, Allianz SE is an insurance provider that operates in 70 countries worldwide. The company offers insurance products and services through its three main segments: health/life insurance, asset management, and property-casualty insurance.

AXA Group, established in 1982, is an insurance company that operates across six distinct segments: Asia, France, the U.S., Europe, transversal and central holdings, and international. The group provides a wide range of products and services across multiple categories, including life and savings, health, property and casualty, banking, and asset management.

The U.S., China, India, Japan, France, Germany, Italy, the U.K., Spain, Switzerland, Australia, Mexico, and Brazil have well-established insurance networks of international players. Additionally, government-mandated insurance policies play a crucial role in driving the growth of both the private and public healthcare insurance industry.

The global private healthcare insurance industry will observe the fastest growth in APAC, particularly in China, India, Australia, and Japan. This growth can be attributed to several factors, such as the increasing healthcare insurance industry, the mounting incidence of chronic illnesses, and rising consciousness regarding healthcare in the region. The growth of the medical tourism industry also contributes to the development of the industry in APAC.

Some of the key players in APAC include Allianz SE, AXA Group, Ping An Insurance (Group) Company of China Ltd., China Life Insurance Co. Ltd., Aetna International, Nippon Life Insurance Company, Allianz SE, Star Health & Allied Insurance Company Limited, Religare Health Insurance Company, and ICICI Lombard General Insurance.

Moreover, the overall dynamics of the healthcare insurance industry in the APAC are undergoing significant changes, driven by improvements in healthcare infrastructure and expenses. As a result, healthcare insurance plans are becoming popular among people in Asia.

Hence, with the increasing elderly population and mounting prevalence of chronic illnesses across the world, the industry of private healthcare insurance will continue to grow in the years to come.

3 agosto 2023

Why Is Autoimmune Disease Diagnostics Demand Rising Robustly?

The Multiple Sclerosis International Federation (MSIF) states that 2.8 million people around the globe were living with multiple sclerosis in 2020, and this autoimmune disease affects around 1 in 3,000 people worldwide. Further, the American Lung Association estimates that approximately 200,000 new cases of sarcoidosis are recorded in the U.S. each year. Additionally, the National Organization for Rare Disorders states that 1 in 10,000 individuals around the world are affected by systemic scleroderma, and this autoimmune disorder is highly prevalent among the Australian and North American populations.

Thus, the increasing prevalence of autoimmune disorders is expected to drive the autoimmune disease diagnostics market at a CAGR of 8.5% during the forecast period 2020–2030. According to P&S Intelligence, the market was valued at $4,086.2 million in 2019, and it will generate $10,012.9 million revenue by 2030. The market growth is also facilitated by the rising public awareness regarding such diseases and the increasing number of awareness programs being organized by public and private organizations to impart knowledge about such disorders.

In recent years, several researchers have discovered new biological markers or biomarkers to diagnose autoimmune diseases. For example, in August 2019, researchers at the University of Alberta discovered a new biological marker to identify the existence of myasthenia gravis, a rare autoimmune disease. This biomarker can also be utilized for formulating new personalized treatment procedures and predicting the course of the disease. Scientists around the world are also discovering biomarkers to detect multiple sclerosis, rheumatoid arthritis (RA), sarcoidosis, scleroderma, systemic lupus erythematosus (SLE), and sjögren’s syndrome.

The product segment of the autoimmune disease diagnostics market is bifurcated into instruments, and consumables and assay kits. Of these, the consumables and assay kits category generated a higher revenue during the historical period (2014–2019), and it is expected to retain its dominance in the forecast years as well. This can be ascribed to the surging incidence of autoimmune diseases and the rising number of research activities to identify the cause of such diseases.

These autoimmune disease diagnostic products are used in academic institutes and research centers, hospitals, and diagnosing centers in autoantibodies and immunology, cytokine, flow cytometry, human leukocyte antigen (HLA), inflammatory marker, and routine laboratory tests. Currently, hospitals are the largest user of such products, owing to the improving healthcare infrastructure, the rising prevalence of chronic autoimmune disorders, the soaring number of awareness programs and campaigns being conducted by public and private organizations, and the increasing deployment of technologically advanced medical devices by these healthcare facilities.

Globally, the North American autoimmune disease diagnostics market generated the highest revenue during the historical period, on account of the mounting healthcare expenditure, soaring aging population, and increasing cases of autoimmune diseases in the region. Additionally, the presence of leading market players also contributes to the regional market growth. Whereas, the Asia-Pacific market is expected to display the fastest growth throughout the forecast period, owing to the booming elderly population and mounting public awareness regarding autoimmune diseases in regional countries.

Therefore, the surging burden of autoimmune diseases and the growing public awareness about such disorders will facilitate the adoption of autoimmune disease diagnostic products, globally.

2 agosto 2023

Medical Gloves Industry To Observe Fastest Growth In Asia-Pacific

As per a statement by P&S Intelligence, the medical gloves industry will reach USD 20,435.6 million, propelling at a rate of 10.8%, by 2030.

The growth in the industry is credited to the increasing elderly population, the growing risk of contagious diseases, mounting healthcare expenses, the growing volume of surgeries, and the increasing incidence of chronic diseases.

The medical gloves industry had been positively affected by the COVID-19 pandemic, due to the sudden surge in medical supplies demand.

Based on raw materials, the nitrile category held the largest share of the medical gloves industry in recent years. This is mainly due to its non-allergic properties.

North America is expected to dominate the industry in the years to come, owing to the widespread necessity for medical gloves in healthcare units, and the existence of strong key players.

Moreover, APAC is expected to witness the fastest growth in the coming years, owing to the increasing elderly populace and rising number of surgical procedures and diagnostic examinations.

A key trend observe in the industry is the fondness for non-powdered medical gloves over powdered medical gloves by the customers, due to the non-allergic properties of the non-powdered medical gloves.

In the past few years, players in the industry have been involved in product launches and mergers & acquisitions to maintain a competitive edge.

Hence, due to the increasing elderly pullulation, increasing incidence of chronic diseases, and growing risk of contagious diseases, the medical gloves industry will continue to grow significantly in the years to come.

1 agosto 2023

Global Facial Skin Ablative Treatment Industry Analysis and Future Scope

The global facial skin ablative treatment market is projected to be worth USD 8,394.3 million by 2030, growing at a CAGR of 7.8%, according to P&S Intelligence. This growth can be ascribed to the growing count of aesthetic measures being conducted throughout the globe, the thriving populace of aging individuals, improvements in technology, growing per-capita income, and rising awareness regarding progressive aesthetic treatments, through meetings and conferences.

On the basis of application, the acne and other scars category had the highest revenue share in the facial skin ablative treatment market in the past few years, and it is projected to remain in the leading position in the future as well. This would mainly be because of the high occurrence of acne in both men and women throughout the world.

The Generation Y category led the industry in recent years, on the basis of demography. This is mainly because of the vast populace of the individuals in this age group, joined by the high occurrence of skin illnesses and rising realization regarding looks among them.

In the past few years, North America held the largest share in the facial skin ablative treatment market, and also the region is projected to be dominant in the future as well.

The Asia-Pacific region is projected to grow at the highest development rate in the facial skin ablative treatment market in the coming few years.

This would mainly be because of the rising healthcare investments and personal per-capita income, growing expenditure by manufacturers, growing aesthetic medicinal tourism industry, and rising populace in the region.

As per the United Nations Department of Economic and Social Affairs (UNDESA), the populace of people aged 65 years and more will touch 225.4 million in India, 356.6 million in China, 52.0 million in Brazil, and 84.8 million in the U.S. by 2050.

Hence, the growing count of aesthetic measures being conducted throughout the globe, the thriving populace of aging individuals, improvements in technology, and growing per-capita income, are the major factors contributing to the growth of the facial skin ablative treatment market.

31 luglio 2023

Europe Is Dominating Vials Industry

The global vials market is projected to be worth USD 3,047.0 million by 2030, growing at a CAGR of 8.6%, according to P&S Intelligence. This growth can be credited to the growing production volume of vial builders, growing healthcare investment, and the rising pharmaceutical sector. Furthermore, the rising demand for vials for the packing of COVID-19 vaccines is boosting industry growth.

In recent years, the borosilicate category had a larger share in the vials industry, on the basis of glass type. Moreover, the category is projected to remain in its dominant position in the future as well.

This is mainly because of the high fondness of vial manufacturing businesses for borosilicate glass because of its chemical inertness, thermal stability, and permeability. Such reasons have, therefore, caused the high requirement for borosilicate vials, mainly to help the continuing COVID vaccination programs throughout the world.

Pharmacological and biotech businesses are projected to establish the fastest-rising category in the vials industry in the coming few years, on the basis of the end user. This can be credited to the increasing demand for superior medications, such as biologics, armed with the rising elderly populace and age-associated ailments. Such reasons are boosting the demand for packing containers, like vials, among pharmacological and biotech businesses throughout the globe.

In recent years, Europe was the largest revenue generator of the vials market. This growth can be credited to the existence of crucial market companies, including Stevanato Group, Schott AG, Gerresheimer AG, and SGD S.A., development in end-use industries, rising elderly populace, augmented knowledge on newly advanced medications, and high disposable income in the continent.

Glass is the more favored material for vials for the vaccine fill–finish procedure, credited to its inertness, durability, robustness, which stops reaction with the medication, and robust resistance to delamination.

Compared to metals and plastics, glass is more appropriate for the main packing of high-end medicinal items. Furthermore, glass vials have a lengthier shelf lifespan and they are biodegradable and environment-friendly as well. Thus, the requirement for such vials is growing globally.

Customer growing knowledge regarding health-associated problems has augmented over the recent years. The growing epidemic of life-intimidating illnesses, like COVID-19, and the constant danger of contagions have resulted in awareness throughout the globe, which is further boosting the utilization of glass vials for medicinal packaging. The increasing expenditure on healthcare in emerging nations, like China and India, is also contributing to the development of the industry.

Hence, the growing production volume of vial builders, growing healthcare investment, and the rising pharmaceutical sector are the major factors contributing to the growth of the vials market.

28 luglio 2023

Benign Prostatic Hyperplasia Treatment Industry Growth and Forecast Report 2023-2030

The benign prostatic hyperplasia treatment market will reach USD 18,837.7 million in 2030, with a CAGR of 5.2% in the years to come. The increasing occurrence of BPH, surging preference for minimally invasive surgeries, and growing investments, funds, and grants for conducting research on novel treatments are the protruding contributors to the development.

The larger share, around 85%, was held by drugs. This is because of the growing requirement for alpha-blockers as these medicines relax the muscle of the prostate and bladder neck, enabling urine flowing more easily.

Amongst the diverse types of drugs, alpha-blockers have been extensively used for treating the disease recently. Their increasing usage and the abundance of medicines under expansion present potential prospects for the industry.

Home healthcare settings had the larger share, and they will record the higher rate, over 5%, in the years to come, as a result of the growing patient count prescribed drugs over surgical treatment.

North America dominated the BPH treatment market with 41% share, as stated by a market research firm, P&S Intelligence. The increasing occurrence of the problem is powering the acceptance of cutting-edge treatments, for example, prostatic stenting, laser therapy, and UroLift therapy, thereby powering the development of the industry in the region.

APAC will grow the fastest in the years to come, at a rate of 6.4%. The improving standards of living, increasing per capita income and spending ability, snowballing burden of urological disease, and increasing investment in the healthcare for boosting the progress.

Furthermore, the increasing aging male population, together with a boom in the occurrence of obesity and diabetes, will power the prevalence of BPH and other lower urinary tract conditions.

China, India and Japan together have a large aging male population, requiring regular medical assistance, being extremely susceptible to chronic ailments as a result of its low immunity.

Therefore, patients with an irregular growth of the prostate are needed to be treated, to prevent urethra blockage and decrease the related cancer risk.

The increasing elderly male population is the main reason for the growing demand for BPH treatment all over the world.

27 luglio 2023

North America Is Dominating Professional Acne Treatment Industry

The global professional acne treatment market is experiencing growth and is projected to reach USD 13,124.5 million by 2030. This development can be credited to the increasing occurrence of acne, rising per-capita income in emerging and emerging nations, growing healthcare expenditure, and the rising count of research events.

In recent years, Inflammatory acne had the largest industry share, on the basis of acne type. This is mainly because of the instant need for better-quality treatment as it is normally painful.

Additionally, the generally accessible salicylic acid and benzoyl-peroxide-based over-the-counter items are not completely effective on inflammatory spots. Then, branded and common medications are provided by key medicinal businesses, on prescription, for inflammatory spots.

In the coming few years, the devices category is projected to experience faster development in the professional acne treatment industry, on the basis of treatment type. This can be ascribed to the increasing acceptance of light-based and laser acne treatments, largely in advanced countries, credited to the side effects of medications.

On the basis of professional type, in recent years, the dermatologist’s category is projected to dominate the professional acne treatment industry. This is mainly because of the growing count of expert dermatologists treating skin illnesses, like acne. Moreover, patients choose dermatologists due to their wide expertise and experience in dealing with the issue.

In recent years, North America led the industry, mainly because of the increasing occurrence of acne, growing knowledge of afresh developed medications, the huge pipeline of medications, and high per-capita income in the continent.

Furthermore, the continent is marked by the existence of protuberant dermatology medication producers, including Pfizer Inc., Johnson & Johnson, and Bausch Health Companies Inc., who offer several classes of medications to the North American populace.

Several pharmaceutical businesses are introducing new products, which have become a key trend in the industry for expert acne treatment items. For example, in 2020, Cassiopea SpA got the U.S. Food and Drug Administration (FDA) sanction for Winlevi, a clascoterone-founded cream made for the cure of acne in patients 13 years and elder.

Furthermore, AnnJi Pharmaceutical Co. Ltd. is involved in the growth of AJ101, which is an up-to-date cream formulation for the cure of acne vulgaris. The active element in AJ101 is a new androgen receptor degradation enhancer, which efficiently reduces the level of activity.

Individuals are concentrating on improving their looks by actively spending on a wide-ranging skincare regimen for scars, acne, and other skin issues. There are numerous treatment choices obtainable, such as systemic agents, topical therapies, lasers, physical modalities, and photodynamic therapy.

Hence, the increasing occurrence of acne, rising per-capita income in emerged and emerging nations, growing healthcare expenditure, and the rising count of research events are the major factors propelling the professional acne treatment market.